knowledge -WSS

knowledge

author：comprehensive 2025-09-29 01:39:10 - browse：4

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Meta looks to target Twitter with a rival app called Threads

hotspot

WSS

Brain 'hot spot' may explain why African Americans feel greater pain

Doctor of U.S. President Joe Biden says he is fit for duty

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Bacterial infection may be ‘key event’ in endometriosis, study says

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Van's Gluten Free Original Waffles recalled for possible wheat allergen

Wikipedia

knowledge

leisure time

Heart attack and stroke risk calculators need revising

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

In age of alternative facts, a scholarly course on calling out crap

Doctor appointment wait times are getting worse

Anesthesiologist group: stop taking Ozempic before surgery

Community addresses injustice for Long Island mothers

Medical leaders decry Supreme Court decision on affirmative action

Using force crossed my mind when examining a defiant young patient

Duchenne breakthrough therapy leaves behind pioneering families

4th of July breaks record for highest global temperature ever measured

explore

7 people shot in DC, police say

Option Care buys Amedisys in $3.6 billion home care deal

Can food be medicine? And other questions about a new push

Brain 'hot spot' may explain why African Americans feel greater pain

Brain 'hot spot' may explain why African Americans feel greater pain

Listen: PBM conflicts, RSV vaccines, & the future of flu season

explore

focus

hotspot

explore